CGL
NVO

Clarius Group LLC’s Novo Nordisk NVO Stock Holding History

Clarius Group LLC’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$322K Sell
6,320
-5,818
-48% -$298K 0.02% 276
2025
Q3 		$674K Sell
12,138
-2,832
-19% -$166K 0.04% 168
2025
Q2 		$1.03M Buy
14,970
+1,689
+13% +$115K 0.06% 142
2025
Q1 		$922K Buy
13,281
+2,351
+22% +$194K 0.06% 154
2024
Q4 		$940K Sell
10,930
-2,762
-20% -$299K 0.06% 133
2024
Q3 		$1.41M Sell
13,692
-1,191
-8% -$159K 0.1% 93
2024
Q2 		$2.12M Sell
14,883
-2,384
-14% -$316K 0.15% 67
2024
Q1 		$2.22M Sell
17,267
-1,238
-7% -$147K 0.15% 65
2023
Q4 		$1.91M Buy
18,505
+93
+0.5% +$9.2K 0.16% 73
2023
Q3 		$1.67M Sell
18,412
-1,014
-5% -$89.3K 0.16% 74
2023
Q2 		$1.57M Buy
19,426
+82
+0.4% +$6.7K 0.12% 93
2023
Q1 		$1.54M Buy
19,344
+186
+1% +$13.2K 0.13% 91
2022
Q4 		$1.3M Sell
19,158
-156
-0.8% -$9.15K 0.12% 103
2022
Q3 		$962K Buy
19,314
+4,324
+29% +$232K 0.1% 122
2022
Q2 		$835K Buy
14,990
+2,930
+24% +$163K 0.08% 146
2022
Q1 		$675K Hold
12,060
– – 0.05% 187
2021
Q4 		$675K Buy
12,060
+1,472
+14% +$79.7K 0.05% 187
2021
Q3 		$508K Buy
10,588
+106
+1% +$5.12K 0.05% 211
2021
Q2 		$439K Buy
10,482
+1,636
+18% +$63.4K 0.04% 237
2021
Q1 		$298K Sell
8,846
-710
-7% -$25.3K 0.03% 289
2020
Q4 		$334K Buy
9,556
+776
+9% +$26.8K 0.04% 239
2020
Q3 		$305K Hold
8,780
– – 0.04% 210
2020
Q2 		$287K Buy
8,780
+264
+3% +$8.43K 0.04% 218
2020
Q1 		$256K Sell
8,516
-4
-0% -$119 0.05% 200
2019
Q4 		$266K Buy
8,520
+170
+2% +$4.71K 0.04% 229
2019
Q3 		$216K Buy
+8,350
New +$211K 0.04% 255

Other funds holding NVO

Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clarius Group LLC's NVO Position: Q4 2025 in Review

Clarius Group LLC reduced its Novo Nordisk (NVO) stake by 48% in Q4 2025, selling an estimated $298K and leaving 6,320 shares worth $322K. The position accounts for 0.02% of the portfolio, ranked #276.

Clarius Group LLC first reported a position in NVO in Q3 2019 and has held it in 26 quarters since. The position peaked at $2.22M in Q1 2024. 1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • Clarius Group LLC held 6,320 shares of Novo Nordisk worth $322K as of Q4 2025.
  • Clarius Group LLC sold 5,818 Novo Nordisk shares in Q4 2025, an estimated $298K.
  • Novo Nordisk made up 0.02% of Clarius Group LLC's portfolio in Q4 2025, its #276 holding.
  • Clarius Group LLC first reported a position in Novo Nordisk in Q3 2019 and has held it in 26 quarters since.
  • Clarius Group LLC's Novo Nordisk position peaked at $2.22M in Q1 2024.
  • 1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.